1
|
Ogawa K, Nishizawa K, Mishiro K, Munekane M, Fuchigami T, Echigo H, Wakabayashi H, Kinuya S. Differences in the Renal Accumulation of Radiogallium-Labeled (Glu) 14 Peptides Containing Different Optical Isomers of Glutamic Acid. Molecules 2024; 29:3993. [PMID: 39274840 PMCID: PMC11396517 DOI: 10.3390/molecules29173993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2024] [Revised: 08/15/2024] [Accepted: 08/21/2024] [Indexed: 09/16/2024] Open
Abstract
Acidic amino acid peptides have a high affinity for bone. Previously, we demonstrated that radiogallium complex-conjugated oligo-acidic amino acids possess promising properties as bone-seeking radiopharmaceuticals. Here, to elucidate the effect of stereoisomers of Glu in Glu-containing peptides [(Glu)14] on their accumulation in the kidney, the biodistributions of [67Ga]Ga-N,N'-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid-conjugated (l-Glu)14 ([67Ga]Ga-HBED-CC-(l-Glu)14), [67Ga]Ga-HBED-CC-(d-Glu)14, [67Ga]Ga-HBED-CC-(dl-Glu)14, and [67Ga]Ga-HBED-CC-(d-Glu-l-Glu)7 were compared. Although the accumulation of these compounds in the bone was comparable, their kidney accumulation and retention were strikingly different, with [67Ga]Ga-HBED-CC-(d-Glu-l-Glu)7 exhibiting the lowest level of kidney accumulation among these compounds. Repeated d- and l-peptides may be a useful method for reducing renal accumulation in some cases.
Collapse
Affiliation(s)
- Kazuma Ogawa
- Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Ishikawa, Japan
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Ishikawa, Japan
| | - Kota Nishizawa
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Ishikawa, Japan
| | - Kenji Mishiro
- Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Ishikawa, Japan
| | - Masayuki Munekane
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Ishikawa, Japan
| | - Takeshi Fuchigami
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Ishikawa, Japan
| | - Hiroaki Echigo
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Ishikawa, Japan
| | - Hiroshi Wakabayashi
- Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Takara-machi 13-1, Kanazawa 920-8641, Ishikawa, Japan
| | - Seigo Kinuya
- Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Takara-machi 13-1, Kanazawa 920-8641, Ishikawa, Japan
| |
Collapse
|
2
|
Ogawa K, Nishizawa K, Mishiro K, Effendi N, Fuchigami T, Munekane M, Wakabayashi H, Kinuya S. Synthesis and Evaluation of Radiogallium Labeled Bone-Imaging Probes Using Oligo-γ-Carboxy Glutamic Acid Peptides as Carriers to Bone. Mol Pharm 2024; 21:2375-2382. [PMID: 38573777 DOI: 10.1021/acs.molpharmaceut.3c01156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/06/2024]
Abstract
We investigated the importance of the carboxy group density in bone affinity during the development of peptide-based bone-seeking radiopharmaceuticals and carriers. Oligo-γ-carboxy glutamic acid peptides [(Gla)n] with higher carboxy group density than oligo-glutamic acid peptides [(Glu)n] and oligo-aspartic acid peptides [(Asp)n] were chosen. Using the radiogallium chelator N,N'-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid (HBED-CC), we synthesized [67Ga]Ga-HBED-CC-(Gla)n (n = 1, 2, 5, 8, 11, or 14) with high yields. Hydroxyapatite-binding assays, biodistribution, and SPECT imaging showed higher affinity and bone accumulation for [67Ga]Ga-HBED-CC-(Gla)n compared to [67Ga]Ga-HBED-CC-(Glu)n. Notably, [67Ga]Ga-HBED-CC-(Gla)8 and [67Ga]Ga-HBED-CC-(Gla)11 exhibited superior bone accumulation and rapid blood clearance. SPECT/CT imaging with [67Ga]Ga-HBED-CC-(Gla)8 exclusively visualized the bone tissue. These findings support the potential use of [67Ga]Ga-HBED-CC-(Gla)n as excellent bone-imaging PET probes, suggesting (Gla)n peptides are superior bone-seeking carriers.
Collapse
Affiliation(s)
- Kazuma Ogawa
- Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan
| | - Kota Nishizawa
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan
| | - Kenji Mishiro
- Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan
| | - Nurmaya Effendi
- Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan
- Faculty of Pharmacy, Universitas Muslim Indonesia, Urip Sumiharjo KM. 10, Makassar 90-231, Indonesia
| | - Takeshi Fuchigami
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan
| | - Masayuki Munekane
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan
| | - Hiroshi Wakabayashi
- Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Takara-machi 13-1, Kanazawa, Ishikawa 920-8641, Japan
| | - Seigo Kinuya
- Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Takara-machi 13-1, Kanazawa, Ishikawa 920-8641, Japan
| |
Collapse
|
3
|
Benfante V, Stefano A, Ali M, Laudicella R, Arancio W, Cucchiara A, Caruso F, Cammarata FP, Coronnello C, Russo G, Miele M, Vieni A, Tuttolomondo A, Yezzi A, Comelli A. An Overview of In Vitro Assays of 64Cu-, 68Ga-, 125I-, and 99mTc-Labelled Radiopharmaceuticals Using Radiometric Counters in the Era of Radiotheranostics. Diagnostics (Basel) 2023; 13:diagnostics13071210. [PMID: 37046428 PMCID: PMC10093267 DOI: 10.3390/diagnostics13071210] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2023] [Revised: 03/11/2023] [Accepted: 03/17/2023] [Indexed: 04/14/2023] Open
Abstract
Radionuclides are unstable isotopes that mainly emit alpha (α), beta (β) or gamma (γ) radiation through radiation decay. Therefore, they are used in the biomedical field to label biomolecules or drugs for diagnostic imaging applications, such as positron emission tomography (PET) and/or single-photon emission computed tomography (SPECT). A growing field of research is the development of new radiopharmaceuticals for use in cancer treatments. Preclinical studies are the gold standard for translational research. Specifically, in vitro radiopharmaceutical studies are based on the use of radiopharmaceuticals directly on cells. To date, radiometric β- and γ-counters are the only tools able to assess a preclinical in vitro assay with the aim of estimating uptake, retention, and release parameters, including time- and dose-dependent cytotoxicity and kinetic parameters. This review has been designed for researchers, such as biologists and biotechnologists, who would like to approach the radiobiology field and conduct in vitro assays for cellular radioactivity evaluations using radiometric counters. To demonstrate the importance of in vitro radiopharmaceutical assays using radiometric counters with a view to radiogenomics, many studies based on 64Cu-, 68Ga-, 125I-, and 99mTc-labeled radiopharmaceuticals have been revised and summarized in this manuscript.
Collapse
Affiliation(s)
- Viviana Benfante
- Ri.MED Foundation, Via Bandiera 11, 90133 Palermo, Italy
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Molecular and Clinical Medicine, University of Palermo, 90127 Palermo, Italy
- Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), 90015 Cefalù, Italy
| | - Alessandro Stefano
- Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), 90015 Cefalù, Italy
| | - Muhammad Ali
- Ri.MED Foundation, Via Bandiera 11, 90133 Palermo, Italy
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Molecular and Clinical Medicine, University of Palermo, 90127 Palermo, Italy
| | | | - Walter Arancio
- Ri.MED Foundation, Via Bandiera 11, 90133 Palermo, Italy
| | - Antonino Cucchiara
- Department of Diagnostic and Therapeutic Services, IRCCS-ISMETT (Mediterranean Institute for Transplantation and Advanced Specialized Therapies), Via Tricomi 5, 90127 Palermo, Italy
| | - Fabio Caruso
- Department of Diagnostic and Therapeutic Services, IRCCS-ISMETT (Mediterranean Institute for Transplantation and Advanced Specialized Therapies), Via Tricomi 5, 90127 Palermo, Italy
| | - Francesco Paolo Cammarata
- Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), 90015 Cefalù, Italy
| | - Claudia Coronnello
- Ri.MED Foundation, Via Bandiera 11, 90133 Palermo, Italy
- National Biodiversity Future Center (NBFC), 90133 Palermo, Italy
| | - Giorgio Russo
- Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), 90015 Cefalù, Italy
- National Biodiversity Future Center (NBFC), 90133 Palermo, Italy
| | - Monica Miele
- Ri.MED Foundation, Via Bandiera 11, 90133 Palermo, Italy
| | - Alessandra Vieni
- Department of Diagnostic and Therapeutic Services, IRCCS-ISMETT (Mediterranean Institute for Transplantation and Advanced Specialized Therapies), Via Tricomi 5, 90127 Palermo, Italy
| | - Antonino Tuttolomondo
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Molecular and Clinical Medicine, University of Palermo, 90127 Palermo, Italy
| | - Anthony Yezzi
- Department of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA
| | - Albert Comelli
- Ri.MED Foundation, Via Bandiera 11, 90133 Palermo, Italy
- National Biodiversity Future Center (NBFC), 90133 Palermo, Italy
| |
Collapse
|
4
|
Adelnia H, Sirous F, Blakey I, Ta HT. Metal ion chelation of poly(aspartic acid): From scale inhibition to therapeutic potentials. Int J Biol Macromol 2023; 229:974-993. [PMID: 36584782 DOI: 10.1016/j.ijbiomac.2022.12.256] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2022] [Revised: 12/21/2022] [Accepted: 12/22/2022] [Indexed: 12/28/2022]
Abstract
Poly(aspartic acid) (PASP) is a biodegradable, biocompatible water-soluble synthetic anionic polypeptide. PASP has shown a strong affinity and thus robust complexation with heavy and alkaline earth metal ions, from which several applications are currently benefiting, and several more could also originate. This paper discusses different areas where the ion chelation ability of PASP has thus far been exploited. Due to its calcium chelation ability, PASP prevents precipitation of calcium salts and hence is widely used as an effective scale inhibitor in industry. Due to potassium chelation, PASP prevents precipitation of potassium tartrate and is employed as an efficient and edible stabilizer for wine preservation. Due to iron chelation, PASP inhibits corrosion of steel surfaces in harsh environments. Due to chelation, PASP can also enhance stability of various colloidal systems that contain metal ions. The chelation ability of PASP alleviated the toxicity of heavy metals in Zebrafish, inhibited the formation of kidney stones and dissolved calcium phosphate which is the main mineral of the calcified vasculature. These findings and beyond, along with the biocompatibility and biodegradability of the polymer could direct future investigations towards chelation therapy by PASP and other novel and undiscovered areas where metal ions play a key role.
Collapse
Affiliation(s)
- Hossein Adelnia
- Queensland Micro-and Nanotechnology Centre, Griffith University, Nathan, Queensland 4111, Australia; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, St Lucia, Queensland 4072, Australia
| | - Fariba Sirous
- Department of Chemistry, Isfahan University of Technology, Isfahan 84156-83111, Iran
| | - Idriss Blakey
- Australian Institute for Bioengineering and Nanotechnology, University of Queensland, St Lucia, Queensland 4072, Australia
| | - Hang Thu Ta
- Queensland Micro-and Nanotechnology Centre, Griffith University, Nathan, Queensland 4111, Australia; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, St Lucia, Queensland 4072, Australia; Bioscience Discipline, School of Environment and Science, Griffith University, Nathan, Queensland 4111, Australia.
| |
Collapse
|
5
|
Seong S, Vijayan V, Kim JH, Kim K, Kim I, Cherukula K, Park IK, Kim N. Nano-formulations for bone-specific delivery of siRNA for CrkII silencing-induced regulation of bone formation and resorption to maximize therapeutic potential for bone-related diseases. Biomater Sci 2023; 11:2581-2589. [PMID: 36794531 DOI: 10.1039/d2bm02038f] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
CrkII, a member of the adaptor protein family, is known to participate in bone homeostasis via the regulation of osteoclasts and osteoblasts. Therefore, silencing CrkII would beneficially impact the bone microenvironment. In this study, CrkII siRNA encapsulated by a bone-targeting peptide (AspSerSer)6-liposome was evaluated for its therapeutic applications using a receptor activator of nuclear factor kappa-B ligand (RANKL)-induced bone loss model. (AspSerSer)6-liposome-siCrkII maintained its gene-silencing ability in both osteoclasts and osteoblasts in vitro and significantly reduced osteoclast formation while increasing osteoblast differentiation in vitro. Fluorescence image analyses showed that the (AspSerSer)6-liposome-siCrkII was present largely in bone, where it remained present for up to 24 hours and was cleared by 48 hours, even when systemically administrated. Importantly, microcomputed-tomography revealed that bone loss induced by RANKL administration was recovered by systemic administration of (AspSerSer)6-liposome-siCrkII. Collectively, the findings of this study suggest that (AspSerSer)6-liposome-siCrkII is a promising therapeutic strategy for the development of treatments for bone diseases, as it overcomes the adverse effects derived from ubiquitous expression via bone-specific delivery of siRNA.
Collapse
Affiliation(s)
- Semun Seong
- Department of Pharmacology, Chonnam National University Medical School, Gwangju 61469, Republic of Korea. .,Hard-Tissue Biointerface Research Center, School of Dentistry, Chonnam National University, Gwangju 61186, Republic of Korea
| | - Veena Vijayan
- Department of Biomedical Sciences and Center for Global Future Biomedical Scientists at Chonnam National University, Chonnam National University Medical School, Gwangju 61469, Republic of Korea.
| | - Jung Ha Kim
- Department of Pharmacology, Chonnam National University Medical School, Gwangju 61469, Republic of Korea. .,Hard-Tissue Biointerface Research Center, School of Dentistry, Chonnam National University, Gwangju 61186, Republic of Korea
| | - Kabsun Kim
- Department of Pharmacology, Chonnam National University Medical School, Gwangju 61469, Republic of Korea.
| | - Inyoung Kim
- Department of Pharmacology, Chonnam National University Medical School, Gwangju 61469, Republic of Korea.
| | - Kondareddy Cherukula
- Department of Biomedical Sciences and Center for Global Future Biomedical Scientists at Chonnam National University, Chonnam National University Medical School, Gwangju 61469, Republic of Korea.
| | - In-Kyu Park
- Department of Biomedical Sciences and Center for Global Future Biomedical Scientists at Chonnam National University, Chonnam National University Medical School, Gwangju 61469, Republic of Korea.
| | - Nacksung Kim
- Department of Pharmacology, Chonnam National University Medical School, Gwangju 61469, Republic of Korea. .,Hard-Tissue Biointerface Research Center, School of Dentistry, Chonnam National University, Gwangju 61186, Republic of Korea
| |
Collapse
|
6
|
Hirata S, Mishiro K, Higashi T, Fuchigami T, Munekane M, Arano Y, Kinuya S, Ogawa K. Synthesis and evaluation of a multifunctional probe with a high affinity for prostate-specific membrane antigen (PSMA) and bone. Nucl Med Biol 2022; 114-115:34-41. [PMID: 36088875 DOI: 10.1016/j.nucmedbio.2022.08.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2022] [Revised: 08/17/2022] [Accepted: 08/18/2022] [Indexed: 12/27/2022]
Abstract
Prostate cancer frequently metastasizes to the bone. Because patients with bone metastases suffer from skeletal-related events, the diagnosis and treatment of bone metastases in the early stage are important. In this study, to improve the sensitivity of detecting bone metastases in patients with prostate cancer, we designed, synthesized, and evaluated a multifunctional radiotracer, [67Ga]Ga-D11-PSMA-617 ([67Ga]3), with an undeca-aspartic acid as a bone-seeking moiety between [67Ga]Ga-DOTA and a prostate-specific membrane antigen (PSMA) ligand based on the lysine-urea-glutamate motif. [67Ga]3 showed a high affinity for hydroxyapatite and high uptake in PSMA-positive LNCaP cells. Moreover, in biodistribution experiments using tumor-bearing mice, [67Ga]3 exhibited high accumulation in the bone and PSMA-positive tumor although the accumulation of [67Ga]3 in the PSMA-positive tumor was lower than that of [67Ga]Ga-PSMA-617. This study provides valuable information for developing radiotheranostic probes combining multiple carriers with different mechanisms.
Collapse
Affiliation(s)
- Saki Hirata
- Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-1192, Japan
| | - Kenji Mishiro
- Institute for Frontier Science Initiative, Kanazawa University, Kanazawa 920-1192, Japan
| | - Takuma Higashi
- Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-1192, Japan
| | - Takeshi Fuchigami
- Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-1192, Japan
| | - Masayuki Munekane
- Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-1192, Japan
| | - Yasushi Arano
- Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 260-8675, Japan
| | - Seigo Kinuya
- Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa University, Kanazawa 920-8641, Japan
| | - Kazuma Ogawa
- Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-1192, Japan; Institute for Frontier Science Initiative, Kanazawa University, Kanazawa 920-1192, Japan.
| |
Collapse
|
7
|
Effendi N, Mishiro K, Wakabayashi H, Gabryel-Skrodzka M, Shiba K, Taki J, Jastrząb R, Kinuya S, Ogawa K. Synthesis and evaluation of radiogallium-labeled long-chain fatty acid derivatives as myocardial metabolic imaging agents. PLoS One 2021; 16:e0261226. [PMID: 34910775 PMCID: PMC8673672 DOI: 10.1371/journal.pone.0261226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2021] [Accepted: 11/25/2021] [Indexed: 11/18/2022] Open
Abstract
Since long-chain fatty acids work as the primary energy source for the myocardium, radiolabeled long-chain fatty acids play an important role as imaging agents to diagnose metabolic heart dysfunction and heart diseases. With the aim of developing radiogallium-labeled fatty acids, herein four fatty acid-based tracers, [67Ga]Ga-HBED-CC-PDA, [67Ga]Ga-HBED-CC-MHDA, [67Ga]Ga-DOTA-PDA, and [67Ga]Ga-DOTA-MHDA, which are [67Ga]Ga-HBED-CC and [67Ga]Ga-DOTA conjugated with pentadecanoic acid (PDA) and 3-methylhexadecanoic acid (MHDA), were synthesized, and their potential for myocardial metabolic imaging was evaluated. Those tracers were found to be chemically stable in 0.1 M phosphate buffered saline. Initial [67Ga]Ga-HBED-CC-PDA, [67Ga]Ga-HBED-CC-MHDA, [67Ga]Ga-DOTA-PDA, and [67Ga]Ga-DOTA-MHDA uptakes in the heart at 0.5 min postinjection were 5.01 ± 0.30%ID/g, 5.74 ± 1.02%ID/g, 5.67 ± 0.22%ID/g, and 5.29 ± 0.10%ID/g, respectively. These values were significantly lower than that of [123I]BMIPP (21.36 ± 2.73%ID/g). For their clinical application as myocardial metabolic imaging agents, further structural modifications are required to increase their uptake in the heart.
Collapse
Affiliation(s)
- Nurmaya Effendi
- Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa, Japan
- Faculty of Pharmacy, Universitas Muslim Indonesia, Makassar, South Sulawesi, Indonesia
| | - Kenji Mishiro
- Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa, Japan
| | - Hiroshi Wakabayashi
- Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa University, Takara-machi, Kanazawa, Ishikawa, Japan
| | | | - Kazuhiro Shiba
- Research Center for Experimental Modeling of Human Disease, Kanazawa University, Takara-machi, Kanazawa, Ishikawa, Japan
| | - Junichi Taki
- Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa University, Takara-machi, Kanazawa, Ishikawa, Japan
| | - Renata Jastrząb
- Faculty of Chemistry, Adam Mickiewicz University in Poznan, Poznan, Poland
| | - Seigo Kinuya
- Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa University, Takara-machi, Kanazawa, Ishikawa, Japan
| | - Kazuma Ogawa
- Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa, Japan
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa, Japan
- * E-mail:
| |
Collapse
|
8
|
Ogawa K, Echigo H, Mishiro K, Hirata S, Washiyama K, Kitamura Y, Takahashi K, Shiba K, Kinuya S. 68Ga- and 211At-Labeled RGD Peptides for Radiotheranostics with Multiradionuclides. Mol Pharm 2021; 18:3553-3562. [PMID: 34403257 DOI: 10.1021/acs.molpharmaceut.1c00460] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Probes for radiotheranostics could be produced by introducing radionuclides with similar chemical characteristics into the same precursors. We recently developed an 211At-labeled RGD peptide and a corresponding radioiodine-labeled RGD peptide. Both labeled peptides accumulated in large quantities in the tumor with similar biodistribution, demonstrating their usefulness for radiotheranostics. In this study, we hypothesized that probes for radiotheranostics combined with multiradionuclides, such as 68Ga and 211At, have useful clinical applications. New radiolabeled RGD peptide probes were synthesized via a molecular design approach, with two labeling sites for metal and halogen. These probes were evaluated in biodistribution experiments using tumor-bearing mice. [67Ga]Ga-DOTA-c[RGDf(4-I)K] ([67Ga]4), Ga-DOTA-[125I]c[RGDf(4-I)K] ([125I]4), and Ga-DOTA-[211At]c[RGDf(4-At)K] ([211At]7) showed similar biodistribution, with high and equivalent accumulation in tumors. These results indicate the usefulness of these probes in radiotheranostics with multiradionuclides, such as a radiometal and a radiohalogen, and they could contribute to a personalized medicine regimen.
Collapse
Affiliation(s)
- Kazuma Ogawa
- Institute for Frontier Science Initiative, Kanazawa University, Kanazawa 920-1192, Japan.,Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-1192, Japan
| | - Hiroaki Echigo
- Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-1192, Japan
| | - Kenji Mishiro
- Institute for Frontier Science Initiative, Kanazawa University, Kanazawa 920-1192, Japan
| | - Saki Hirata
- Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-1192, Japan
| | - Kohshin Washiyama
- Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan
| | - Yoji Kitamura
- Research Center for Experimental Modeling of Human Disease, Kanazawa University, Takara-machi 13-1, Kanazawa, Ishikawa 920-8640, Japan
| | - Kazuhiro Takahashi
- Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan
| | - Kazuhiro Shiba
- Research Center for Experimental Modeling of Human Disease, Kanazawa University, Takara-machi 13-1, Kanazawa, Ishikawa 920-8640, Japan
| | - Seigo Kinuya
- Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa University, Takara-machi 13-1, Kanazawa, Ishikawa 920-8641, Japan
| |
Collapse
|
9
|
Adelnia H, Tran HDN, Little PJ, Blakey I, Ta HT. Poly(aspartic acid) in Biomedical Applications: From Polymerization, Modification, Properties, Degradation, and Biocompatibility to Applications. ACS Biomater Sci Eng 2021; 7:2083-2105. [PMID: 33797239 DOI: 10.1021/acsbiomaterials.1c00150] [Citation(s) in RCA: 38] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Poly(aspartic acid) (PASP) is an anionic polypeptide that is a highly versatile, biocompatible, and biodegradable polymer that fulfils key requirements for use in a wide variety of biomedical applications. The derivatives of PASP can be readily tailored via the amine-reactive precursor, poly(succinimide) (PSI), which opens up a large window of opportunity for the design and development of novel biomaterials. PASP also has a strong affinity with calcium ions, resulting in complexation, which has been exploited for bone targeting and biomineralization. In addition, recent studies have further verified the biocompatibility and biodegradability of PASP-based polymers, which is attributed to their protein-like structure. In light of growing interest in PASP and its derivatives, this paper presents a comprehensive review on their synthesis, characterization, modification, biodegradation, biocompatibility, and applications in biomedical areas.
Collapse
Affiliation(s)
- Hossein Adelnia
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland 4072, Australia.,Queensland Micro- and Nanotechnology, Griffith University, Nathan, Queensland 4111, Australia.,School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Woolloongabba, Queensland 4012, Australia
| | - Huong D N Tran
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland 4072, Australia.,Queensland Micro- and Nanotechnology, Griffith University, Nathan, Queensland 4111, Australia
| | - Peter J Little
- School of Pharmacy, Pharmacy Australia Centre of Excellence, The University of Queensland, Woolloongabba, Queensland 4012, Australia.,Sunshine Coast Health Institute, University of the Sunshine Coast, Birtinya, Queensland 4575, Australia
| | - Idriss Blakey
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland 4072, Australia.,Centre for Advanced Imaging, University of Queensland, Brisbane, Queensland 4067, Australia
| | - Hang T Ta
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland 4072, Australia.,Queensland Micro- and Nanotechnology, Griffith University, Nathan, Queensland 4111, Australia.,School of Environment and Science, Griffith University, Nathan, Queensland 411, Australia
| |
Collapse
|
10
|
Effendi N, Mishiro K, Shiba K, Kinuya S, Ogawa K. Development of Radiogallium-Labeled Peptides for Platelet-Derived Growth Factor Receptor β (PDGFR β) Imaging: Influence of Different Linkers. Molecules 2020; 26:molecules26010041. [PMID: 33374773 PMCID: PMC7795354 DOI: 10.3390/molecules26010041] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Revised: 12/17/2020] [Accepted: 12/21/2020] [Indexed: 12/11/2022] Open
Abstract
The purpose of this study is to develop peptide-based platelet-derived growth factor receptor β (PDGFRβ) imaging probes and examine the effects of several linkers, namely un-natural amino acids (D-alanine and β-alanine) and ethylene-glycol (EG), on the properties of Ga-DOTA-(linker)-IPLPPPRRPFFK peptides. Seven radiotracers, 67Ga-DOTA-(linker)-IPLPPPRRPFFK peptides, were designed, synthesized, and evaluated. The stability and cell uptake in PDGFRβ positive peptide cells were evaluated in vitro. The biodistribution of [67Ga]Ga-DOTA-EG2-IPLPPPRRPFFK ([67Ga]27) and [67Ga]Ga-DOTA-EG4-IPLPPPRRPFFK ([67Ga]28), which were selected based on in vitro stability in murine plasma and cell uptake rates, were determined in BxPC3-luc-bearing nu/nu mice. Seven 67Ga-labeled peptides were successfully synthesized with high radiochemical yields (>85%) and purities (>99%). All evaluated radiotracers were stable in PBS (pH 7.4) at 37 °C. However, only [67Ga]27 and [67Ga]28 remained more than 75% after incubation in murine plasma at 37 °C for 1 h. [67Ga]27 exhibited the highest BxPC3-luc cell uptake among the prepared radiolabeled peptides. As regards the results of the biodistribution experiments, the tumor-to-blood ratios of [67Ga]27 and [67Ga]28 at 1 h post-injection were 2.61 ± 0.75 and 2.05 ± 0.77, respectively. Co-injection of [67Ga]27 and an excess amount of IPLPPPRRPFFK peptide as a blocking agent can significantly decrease this ratio. However, tumor accumulation was not considered sufficient. Therefore, further probe modification is required to assess tumor accumulation for in vivo imaging.
Collapse
Affiliation(s)
- Nurmaya Effendi
- Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan; (N.E.); (K.M.)
- Faculty of Pharmacy, Universitas Muslim Indonesia, Urip Sumiharjo KM. 10, Makassar 90-231, Indonesia
| | - Kenji Mishiro
- Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan; (N.E.); (K.M.)
| | - Kazuhiro Shiba
- Advanced Science Research Center, Kanazawa University, Takara-machi 13-1, Kanazawa, Ishikawa 920-8640, Japan;
| | - Seigo Kinuya
- Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Takara-machi 13-1, Kanazawa, Ishikawa 920-8641, Japan;
| | - Kazuma Ogawa
- Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan; (N.E.); (K.M.)
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan
- Correspondence: ; Tel./Fax: +81-76-234-4460
| |
Collapse
|
11
|
Rotman SG, Moriarty TF, Nottelet B, Grijpma DW, Eglin D, Guillaume O. Poly(Aspartic Acid) Functionalized Poly(ϵ-Caprolactone) Microspheres with Enhanced Hydroxyapatite Affinity as Bone Targeting Antibiotic Carriers. Pharmaceutics 2020; 12:pharmaceutics12090885. [PMID: 32957602 PMCID: PMC7559286 DOI: 10.3390/pharmaceutics12090885] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2020] [Revised: 09/08/2020] [Accepted: 09/14/2020] [Indexed: 12/11/2022] Open
Abstract
Bone infection is a feared complication for patients with surgically fixed bone fractures and local antibiotic delivery is important in prophylaxis and treatment of these infections. Recent studies indicated that Staphylococcus aureus can penetrate bone tissue through micron-sized canaliculi and evade systemic and currently available local antibiotic treatments. Targeting bacteria within the bone requires highly efficient delivery of antimicrobials to the infected bone tissue. In this work, a biodegradable microsphere carrier loaded with antibiotics and with specific affinity to bone mineral was developed. Two widely used antibiotics, i.e., Gentamicin-dioctyl sulfosuccinate (GM-AOT) and Ciprofloxacin (CF) were embedded in poly(ϵ-caprolactone) (PCL) microspheres fabricated by oil-in-water emulsion techniques with carboxylated poly(vinyl alcohol) (cPVA) as surfactant. The carboxylic acid groups present at the Poly(ϵ-caprolactone)/cPVA (PCL-cPVA) microsphere surface were functionalized with aspartic acid oligomers (ASP) granting bone targeting properties. We report on cPVA synthesis, microsphere formulation, and antibiotic loading of PCL/cPVA-ASP microspheres. Antibiotic loaded PCL/cPVA-ASP microspheres show sustained release of its antibiotic load and can inhibit bacterial growth in vitro for up to 6 days. PCL/cPVA-ASP microspheres show enhanced affinity to mineralized substrates compared to non-functionalized PCL/cPVA microspheres. These findings support further development of these bone targeting antibiotic carriers for potential treatment of persistent bone infections.
Collapse
Affiliation(s)
- Stijn G. Rotman
- AO Research Institute Davos, 7270 Davos Platz, Switzerland; (S.G.R.); (T.F.M.); (D.E.)
- Department of Biomaterials Science and Technology, Faculty of Science and Technology and Technical Medical Centre, University of Twente, 7522 NB Enschede, The Netherlands;
| | - Thomas F. Moriarty
- AO Research Institute Davos, 7270 Davos Platz, Switzerland; (S.G.R.); (T.F.M.); (D.E.)
| | - Benjamin Nottelet
- IBMM, University of Montpellier, CNRS, ENSCM, 34093 Montpellier, France;
| | - Dirk W. Grijpma
- Department of Biomaterials Science and Technology, Faculty of Science and Technology and Technical Medical Centre, University of Twente, 7522 NB Enschede, The Netherlands;
| | - David Eglin
- AO Research Institute Davos, 7270 Davos Platz, Switzerland; (S.G.R.); (T.F.M.); (D.E.)
- Department of Biomaterials Science and Technology, Faculty of Science and Technology and Technical Medical Centre, University of Twente, 7522 NB Enschede, The Netherlands;
| | - Olivier Guillaume
- Institute of Materials Science and Technology, TU Wien, 1060 Vienna, Austria
- Correspondence:
| |
Collapse
|
12
|
Nakamura S, Matsuno A, Ueda M. Improvement of biodistribution profile of a radiogallium-labeled, αvβ6 integrin-targeting peptide probe by incorporation of negatively charged amino acids. Ann Nucl Med 2020; 34:575-582. [DOI: 10.1007/s12149-020-01483-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Accepted: 06/01/2020] [Indexed: 11/24/2022]
|
13
|
Melnyk T, Đorđević S, Conejos-Sánchez I, Vicent MJ. Therapeutic potential of polypeptide-based conjugates: Rational design and analytical tools that can boost clinical translation. Adv Drug Deliv Rev 2020; 160:136-169. [PMID: 33091502 DOI: 10.1016/j.addr.2020.10.007] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2020] [Revised: 10/09/2020] [Accepted: 10/14/2020] [Indexed: 12/14/2022]
Abstract
The clinical success of polypeptides as polymeric drugs, covered by the umbrella term "polymer therapeutics," combined with related scientific and technological breakthroughs, explain their exponential growth in the development of polypeptide-drug conjugates as therapeutic agents. A deeper understanding of the biology at relevant pathological sites and the critical biological barriers faced, combined with advances regarding controlled polymerization techniques, material bioresponsiveness, analytical methods, and scale up-manufacture processes, have fostered the development of these nature-mimicking entities. Now, engineered polypeptides have the potential to combat current challenges in the advanced drug delivery field. In this review, we will discuss examples of polypeptide-drug conjugates as single or combination therapies in both preclinical and clinical studies as therapeutics and molecular imaging tools. Importantly, we will critically discuss relevant examples to highlight those parameters relevant to their rational design, such as linking chemistry, the analytical strategies employed, and their physicochemical and biological characterization, that will foster their rapid clinical translation.
Collapse
Affiliation(s)
- Tetiana Melnyk
- Centro de Investigación Príncipe Felipe, Polymer Therapeutics Lab, Av. Eduardo Primo Yúfera 3, E-46012 Valencia, Spain.
| | - Snežana Đorđević
- Centro de Investigación Príncipe Felipe, Polymer Therapeutics Lab, Av. Eduardo Primo Yúfera 3, E-46012 Valencia, Spain.
| | - Inmaculada Conejos-Sánchez
- Centro de Investigación Príncipe Felipe, Polymer Therapeutics Lab, Av. Eduardo Primo Yúfera 3, E-46012 Valencia, Spain.
| | - María J Vicent
- Centro de Investigación Príncipe Felipe, Polymer Therapeutics Lab, Av. Eduardo Primo Yúfera 3, E-46012 Valencia, Spain.
| |
Collapse
|
14
|
Liu Y, Miao YL, Qin F, Cao C, Yu XL, Wu YH, Wang TL, Xu RG, Zhao L, Wu F, Zhang ZC, Yang JM, Yang Y, Xie X, Zhang LM, Deng FL. Electrospun Poly (Aspartic Acid)-Modified Zein Nanofibers for Promoting Bone Regeneration. Int J Nanomedicine 2019; 14:9497-9512. [PMID: 31819446 PMCID: PMC6898722 DOI: 10.2147/ijn.s224265] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Accepted: 11/13/2019] [Indexed: 01/04/2023] Open
Abstract
Background Critical-sized bone defects raise great challenges. Zein is of interest for bone regeneration, but it has limited ability to stimulate cell proliferation. In this regard, a poly (aspartic acid) (PAsp)-zein hybrid is promising, as PAsp can promote rat bone marrow stromal cell (rBMSCs) proliferation and osteogenic differentiation. This research aimed to develop electrospun PAsp-modified zein nanofibers to realize critical-sized bone defects repair. Methods Three groups of PAsp-modified zein nanofibers were prepared, they were PAsp grafting percentages of 0% (zein), 5.32% (ZPAA-1), and 7.63% (ZPAA-2). Using rBMSCs as in vitro cell model and SD rats as in vivo animal model, fluorescence staining, SEM, CCK-8, ALP, ARS staining, μCT and histological analysis were performed to verify the biological and osteogenic activities for PAsp-modified zein nanofibers. Results As the Asp content increased from 0% to 7.63%, the water contact angle decreased from 129.8 ± 2.3° to 105.5 ± 2.5°. SEM, fluorescence staining and CCK-8 assay showed that ZPAA-2 nanofibers had a superior effect on rBMSCs spreading and proliferation than did zein and ZPAA-1 nanofibers, ALP activity and ARS staining showed that ZPAA-2 can improve rBMSCs osteogenic differentiation. In vivo osteogenic activities was evaluated by μCT analysis, HE, Masson and immunohistochemical staining, indicating accelerated bone formation in ZPAA-2 SD rats after 4 and 8 weeks treatment, with a rank order of ZPAA-2 > ZPAA-1 > zein group. Moreover, the semiquantitative results of the Masson staining revealed that the maturity of the new bone was higher in the ZPAA-2 group than in the other groups. Conclusion Electrospun PAsp-modified zein can provide a suitable microenvironment for osteogenic differentiation of rBMSCs, as well as for bone regeneration; the optimal membrane appears to have a PAsp grafting percentage of 7.63%.
Collapse
Affiliation(s)
- Yun Liu
- Department of Oral Implantology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China
| | - Ying-Ling Miao
- School of Materials Science and Engineering, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China
| | - Feng Qin
- Department of Oral Implantology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China
| | - Cen Cao
- Department of Oral Implantology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China
| | - Xiao-Lin Yu
- Department of Oral Implantology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China
| | - Yu-Han Wu
- Department of Oral Implantology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China
| | - Tian-Lu Wang
- Department of Oral Implantology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China
| | - Ruo-Gu Xu
- Department of Oral Implantology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China
| | - Liu Zhao
- School of Chemistry, Beihang University, Beijing, People's Republic of China
| | - Fan Wu
- Department of Oral Implantology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China
| | - Zheng-Chuan Zhang
- Department of Oral Implantology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China
| | - Jia-Min Yang
- Department of Oral Implantology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China
| | - Yang Yang
- Department of Oral Implantology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China
| | - Xin Xie
- Department of Oral Implantology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China
| | - Li-Ming Zhang
- School of Materials Science and Engineering, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China
| | - Fei-Long Deng
- Department of Oral Implantology, Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China
| |
Collapse
|
15
|
Ishizaki A, Mishiro K, Shiba K, Hanaoka H, Kinuya S, Odani A, Ogawa K. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives. Ann Nucl Med 2019; 33:244-251. [PMID: 30604401 DOI: 10.1007/s12149-018-01326-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2018] [Accepted: 12/20/2018] [Indexed: 01/10/2023]
Abstract
OBJECTIVE Somatostatin receptors are highly expressed in neuroendocrine tumors, and many radiolabeled somatostatin analogs for diagnosis and treatment have been developed. To simultaneously detect not only primary cancer but also bone metastases, this study aimed to develop a positron emission tomography probe using generator-produced nuclide Gallium-68 (T1/2 = 68 min), in which a carrier for primary cancer, a carrier for bone metastases lesions, and a stable gallium complex are introduced into the one molecule. Based on this strategy, the somatostatin receptor-targeted peptide, [Tyr3]-octreotate (TATE), aspartic acid peptide (Dn) with high binding affinity for hydroxyapatite, and Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) as a stable gallium complex were selected. The novel complexes, Ga-DOTA-Dn-TATE (n = 0, 2, 5, 8, or 11), were designed, synthesized, and evaluated. The radiogallium complexes were prepared using the easy-to-handle radioisotope 67Ga due to relatively long half-life. METHODS The radiogallium complex precursor DOTA-Dn-TATE was synthesized by the Fmoc-based solid-phase method and by the air oxidation method to form the disulfide bond. [67Ga]Ga-DOTA-Dn-TATE was synthesized by reacting DOTA-Dn-TATE and 67Ga. Hydroxyapatite binding assays, in vitro cellular uptake experiments in AR42J tumor cells, in biodistribution experiments in AR42J tumor-bearing mice, were performed using [67Ga]Ga-DOTA-Dn-TATE. RESULTS The radiochemical purities of [67Ga]Ga-DOTA-Dn-TATE were > 96.0%. In in vitro and in vivo experiments, [67Ga]Ga-DOTA-D11-TATE had a high affinity for hydroxyapatite and highly accumulated in bone. However, the uptake of [67Ga]Ga-DOTA-D11-TATE into somatostatin receptor-positive AR42J cells was lower than that of [67Ga]Ga-DOTA-TATE, and the accumulation of [67Ga]Ga-DOTA-D11-TATE in tumor was significantly low. CONCLUSION Ga-DOTA-D11-TATE may not be recognized by somatostatin receptor by the introduction of D11, and the charge adjustment may be important for somatostatin receptor-positive cell uptake.
Collapse
Affiliation(s)
- Atsushi Ishizaki
- Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
| | - Kenji Mishiro
- Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa, Japan
| | - Kazuhiro Shiba
- Advanced Science Research Center, Kanazawa University, Kanazawa, Japan
| | - Hirofumi Hanaoka
- Department of Bioimaging Information Analysis, Graduate School of Medicine, Gunma University, Maebashi, Japan
| | - Seigo Kinuya
- Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
| | - Akira Odani
- Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
| | - Kazuma Ogawa
- Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan. .,Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa, Japan.
| |
Collapse
|
16
|
Yavvari PS, Awasthi AK, Sharma A, Bajaj A, Srivastava A. Emerging biomedical applications of polyaspartic acid-derived biodegradable polyelectrolytes and polyelectrolyte complexes. J Mater Chem B 2019; 7:2102-2122. [DOI: 10.1039/c8tb02962h] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
A summary of positive biomedical attributes of biodegradable polyelectrolytes (PELs) prepared from aspartic acid is provided. The utility of these PELs in emerging applications such as biomineralization modulators, antimycobacterials, biocompatible cell encapsulants and tissue adhesives is highlighted.
Collapse
Affiliation(s)
- Prabhu Srinivas Yavvari
- Department of Chemistry
- Indian Institute of Science Education and Research
- Bhauri
- Bhopal-462066
- India
| | - Anand Kumar Awasthi
- Department of Chemistry
- Indian Institute of Science Education and Research
- Bhauri
- Bhopal-462066
- India
| | - Aashish Sharma
- Department of Chemistry
- Indian Institute of Science Education and Research
- Bhauri
- Bhopal-462066
- India
| | - Avinash Bajaj
- Laboratory of Nanotechnology and Chemical Biology
- Regional Centre for Biotechnology
- NCR Biotech Science Cluster
- Faridabad-121001
- India
| | - Aasheesh Srivastava
- Department of Chemistry
- Indian Institute of Science Education and Research
- Bhauri
- Bhopal-462066
- India
| |
Collapse
|
17
|
Ogawa K. Development of Diagnostic and Therapeutic Probes with Controlled Pharmacokinetics for Use in Radiotheranostics. Chem Pharm Bull (Tokyo) 2019; 67:897-903. [PMID: 31474726 DOI: 10.1248/cpb.c19-00274] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The word "theranostics," a portmanteau word made by combining "therapeutics" and "diagnostics," refers to a personalized medicine concept. Recently, the word, "radiotheranostics," has also been used in nuclear medicine as a term that refer to the use of radioisotopes for combined imaging and therapy. For radiotheranostics, a diagnostic probe and a corresponding therapeutic probe can be prepared by introducing diagnostic and therapeutic radioisotopes into the same precursor. These diagnostic and therapeutic probes can be designed to show equivalent pharmacokinetics, which is important for radiotheranostics. As imaging can predict the absorbed radiation dose and thus the therapeutic and side effects, radiotheranostics can help achieve the goal of personalized medicine. In this review, I discuss the use of radiolabeled probes targeting bone metastases, sigma-1 receptor, and αVβ3 integrin for radiotheranostics.
Collapse
Affiliation(s)
- Kazuma Ogawa
- Institute for Frontier Science Initiative, Kanazawa University
- Graduate School of Medical Sciences, Kanazawa University
| |
Collapse
|
18
|
Effendi N, Mishiro K, Takarada T, Makino A, Yamada D, Kitamura Y, Shiba K, Kiyono Y, Odani A, Ogawa K. Radiobrominated benzimidazole-quinoline derivatives as Platelet-derived growth factor receptor beta (PDGFRβ) imaging probes. Sci Rep 2018; 8:10369. [PMID: 29991770 PMCID: PMC6039436 DOI: 10.1038/s41598-018-28529-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Accepted: 06/25/2018] [Indexed: 12/31/2022] Open
Abstract
Platelet-derived growth factor receptor beta (PDGFRβ) affects in numerous human cancers and has been recognized as a promising molecular target for cancer therapies. The overexpression of PDGFRβ could be a biomarker for cancer diagnosis. Radiolabeled ligands having high affinity for the molecular target could be useful tools for the imaging of overexpressed receptors in tumors. In this study, we aimed to develop radiobrominated PDGFRβ ligands and evaluate their effectiveness as PDGFRβ imaging probes. The radiolabeled ligands were designed by modification of 1-{2-[5-(2-methoxyethoxy)-1H- benzo[d]imidazol-1-yl]quinolin-8-yl}piperidin-4-amine (1), which shows selective inhibition profile toward PDGFRβ. The bromine atom was introduced directly into C-5 of the quinoline group of 1, or indirectly by the conjugation of 1 with the 3-bromo benzoyl group. [77Br]1-{5-Bromo-2-[5-(2-methoxyethoxy)-1H-benzo[d]imidazol-1-yl]quinoline-8-yl}piperidin-4-amine ([77Br]2) and [77Br]-N-3-bromobenzoyl-1-{2-[5-(2-methoxyethoxy)-1H-benzo[d]imidazol-1-yl]quinolin-8-yl}-piperidin-4-amine ([77Br]3) were prepared using a bromodestannylation reaction. In a cellular uptake study, [77Br]2 and [77Br]3 more highly accumulatd in BxPC3-luc cells (PDGFRβ-positive) than in MCF7 cells (PDGFRβ-negative), and their accumulation was significantly reduced by pretreatment with inhibitors. In biodistribution experiments, [77Br]2 accumulation was higher than [77Br]3 accumulation at 1 h postinjection. These findings suggest that [76Br]2 is more promising for positron emission tomography (PET) imaging of PDGFRβ than [76Br]3.
Collapse
Affiliation(s)
- Nurmaya Effendi
- Kanazawa University, Graduate School of Pharmaceutical Sciences, Kakuma-machi, Kanazawa, 920-1192, Japan
- Universitas Muslim Indonesia, Faculty of Pharmacy, Urip Sumiharjo KM. 10, Makassar, 90-231, Indonesia
| | - Kenji Mishiro
- Kanazawa University, Institute for Frontier Science Initiative, Kakuma-machi, Kanazawa, 920-1192, Japan
| | - Takeshi Takarada
- Okayama University, Graduate School of Medicine, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan
| | - Akira Makino
- University of Fukui, Biomedical Imaging Research Center, 23-3 Matsuoka Shimoaizuki, Yoshida, 910-1193, Japan
| | - Daisuke Yamada
- Okayama University, Graduate School of Medicine, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan
| | - Yoji Kitamura
- Kanazawa University, Advanced Science Research Centre, 13-1 Takara-machi, Kanazawa, 920-8640, Japan
| | - Kazuhiro Shiba
- Kanazawa University, Advanced Science Research Centre, 13-1 Takara-machi, Kanazawa, 920-8640, Japan
| | - Yasushi Kiyono
- University of Fukui, Biomedical Imaging Research Center, 23-3 Matsuoka Shimoaizuki, Yoshida, 910-1193, Japan
| | - Akira Odani
- Kanazawa University, Graduate School of Pharmaceutical Sciences, Kakuma-machi, Kanazawa, 920-1192, Japan
| | - Kazuma Ogawa
- Kanazawa University, Graduate School of Pharmaceutical Sciences, Kakuma-machi, Kanazawa, 920-1192, Japan.
- Kanazawa University, Institute for Frontier Science Initiative, Kakuma-machi, Kanazawa, 920-1192, Japan.
| |
Collapse
|
19
|
Totsingan F, Centore R, Gross RA. CAL-B catalyzed regioselective bulk polymerization of l-aspartic acid diethyl ester to α-linked polypeptides. Chem Commun (Camb) 2018; 53:4030-4033. [PMID: 28345083 DOI: 10.1039/c7cc01300k] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
This paper reports that the bulk polymerization of l-aspartic acid diethyl ester catalyzed by immobilized CAL-B at 80 °C for 24 h gives primarily (∼95%) α-linked poly(l-aspartate) in 70% yield with DPavg = 50 and regioselectivity (α/β) = 94 : 6. Plots of log{[M]0/[M]t} vs. time and DPavgvs. conversion indicate that this polymerization proceeds in a controlled manner by a chain-growth mechanism up to 90% conversion. Thereafter, competition occurs between chain growth and step mechanisms.
Collapse
Affiliation(s)
- Filbert Totsingan
- Department of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute (RPI), 4005B Biotechnology Building, 110 Eighth Street, Troy, New York 12180, USA.
| | - Robert Centore
- Department of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute (RPI), 4005B Biotechnology Building, 110 Eighth Street, Troy, New York 12180, USA.
| | - Richard A Gross
- Department of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute (RPI), 4005B Biotechnology Building, 110 Eighth Street, Troy, New York 12180, USA.
| |
Collapse
|
20
|
Targeted drug delivery for tumor therapy inside the bone marrow. Biomaterials 2018; 155:191-202. [DOI: 10.1016/j.biomaterials.2017.11.029] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2017] [Revised: 10/26/2017] [Accepted: 11/21/2017] [Indexed: 12/18/2022]
|
21
|
Yamashita S, Katsumi H, Hibino N, Isobe Y, Yagi Y, Tanaka Y, Yamada S, Naito C, Yamamoto A. Development of PEGylated aspartic acid-modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis. Biomaterials 2017; 154:74-85. [PMID: 29120820 DOI: 10.1016/j.biomaterials.2017.10.053] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2017] [Revised: 10/30/2017] [Accepted: 10/30/2017] [Indexed: 10/18/2022]
Abstract
To prevent bone metastasis, we developed polyethylene glycol (PEG)-conjugated aspartic acid (Asp)-modified liposomes (PEG-Asp-Lipo) as a bone-targeting carrier of paclitaxel (PTX) by using Asp-modified 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE-Asp). The affinity of Asp-modified liposomes to hydroxyapatite increased as the concentration of DPPE-Asp increased. The bone accumulation of [3H]-labeled PEG(2)-Asp(33)-Lipo was approximately 24.6% 360 min after intravenous injection in mice, in contrast to 5.4% and 6.7% of [3H]-labeled normal Lipo and PEG(2)-Lipo, respectively. Similarly, [14C]-labeled PTX encapsulated into PEG(2)-Asp(33)-Lipo predominantly accumulated in the bone. Furthermore, using an in situ imaging experiment, we observed that near-infrared fluorescence-labeled PEG(2)-Asp(33)-Lipo selectively accumulated in the bone near the joint after intravenous injection in mice. We also found that FITC-labeled PEG(2)-Asp(33)-Lipo predominantly accumulated on eroded and quiescent bone surfaces. In a bone metastatic tumor mouse model, in which B16-BL6/Luc cells were injected into the left ventricle of female C57BL/6 mice, metastatic bone tumor growth was significantly inhibited by an intravenous injection of PEG(2)-Asp(33)-liposomal PTX. In contrast, PEGylated liposomal PTX hardly affected the growth of metastatic bone tumors. These findings indicate that PEG(2)-Asp(33)-Lipo is a promising bone-targeting carrier for the delivery of PTX and treatment of bone metastasis.
Collapse
Affiliation(s)
- Shugo Yamashita
- Department of Biopharmaceutics, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8414, Japan
| | - Hidemasa Katsumi
- Department of Biopharmaceutics, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8414, Japan.
| | - Nozomi Hibino
- Department of Biopharmaceutics, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8414, Japan
| | - Yugo Isobe
- Department of Biopharmaceutics, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8414, Japan
| | - Yumiko Yagi
- Department of Biopharmaceutics, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8414, Japan
| | - Yuka Tanaka
- Department of Biopharmaceutics, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8414, Japan
| | - Saki Yamada
- Department of Biopharmaceutics, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8414, Japan
| | - Chihiro Naito
- Department of Biopharmaceutics, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8414, Japan
| | - Akira Yamamoto
- Department of Biopharmaceutics, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8414, Japan
| |
Collapse
|
22
|
Evaluation of Ga-DOTA-(D-Asp) n as bone imaging agents: D-aspartic acid peptides as carriers to bone. Sci Rep 2017; 7:13971. [PMID: 29070853 PMCID: PMC5656653 DOI: 10.1038/s41598-017-14149-7] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2017] [Accepted: 10/05/2017] [Indexed: 12/12/2022] Open
Abstract
67Ga-DOTA-(L-Asp)11 and 67Ga-DOTA-(L-Asp)14, which have been developed as bone imaging agents, showed a high accumulation in bone and a rapid blood clearance in mice. However, peptides composed of D-amino acids are more stable in vivo than those composed of their L-equivalents. In this study, 67Ga-DOTA-(D-Asp)n (n = 2, 5, 8, 11, or 14) were synthesized using the Fmoc-based solid-phase methodology and evaluated. In hydroxyapatite binding assay, binding of 67Ga-DOTA-(D-Asp)n tended to increase with increasing length of the amino acid chain. 67Ga-DOTA-(D-Asp)11 and 67Ga-DOTA-(D-Asp)14 caused a high accumulation of radioactivity in the bones of the mice. However, the results for 67Ga-DOTA-(D-Asp)n and 67Ga-DOTA-(L-Asp)n were comparable. In urine analyses, the proportion of intact complex after injection of 67Ga-DOTA-(D-Asp)14 was significantly higher than that of 67Ga-DOTA-(L-Asp)14. Although 67Ga-DOTA-(D-Asp)14 was more stable than 67Ga-DOTA-(L-Asp)14, the properties of 67Ga-DOTA-(D-Asp)n and 67Ga-DOTA-(L-Asp)n as bone imaging agents may be comparable.
Collapse
|
23
|
Jaswal AP, Meena VK, Prakash S, Pandey A, Singh B, Mishra AK, Hazari PP. [ 68Ga]/[ 188Re] Complexed [CDTMP] Trans-1,2-Cyclohexyldinitrilotetraphosphonic Acid As a Theranostic Agent for Skeletal Metastases. Front Med (Lausanne) 2017. [PMID: 28649566 PMCID: PMC5465288 DOI: 10.3389/fmed.2017.00072] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Objective Metastasis of the osseous tissue is one of the frequent and severe aggravations as a result of several neoplastic conditions, such as metabolic disorders, infections, and cancer. The objective of this study was to evaluate the pertinence of [68Ga]-trans-1,2-cyclohexyldinitrilo tetramethylene phosphonic acid (CDTMP) as a potential bone imaging agent for positron emission tomography (PET) applications as well as to assess [188Re]-CDTMP for bone pain palliation in metastatic skeletal disorders. Methods 68Ga complex of CDTMP was prepared at 80°C at pH 3.5, and 188Re complex of CDTMP was prepared at room temperature. [68Ga]-CDTMP complex was investigated as PET tracer while the therapeutic efficacy was assessed for [188Re]-CDTMP. Labeling efficiency, biodistribution, myelotoxicity, and imaging studies were carried out for the complexes synthesized. Both PET and MicroPET imaging studies were performed for [68Ga]-CDTMP whereas SPECT acquisitions were acquired for [188Re]-CDTMP. Data were analyzed semiquantitatively for all the scintigraphic scans obtained. Results The radiolabeling efficiency was observed to be >70% for [68Ga]-CDTMP. High bone uptake of [68Ga]-CDTMP as compared to contralateral tissue was found in PET imaging in Balb/C mice and New Zealand rabbit; the similar result for bone uptake was correlated in the biodistribution study of the compound in BALB/c mice at different time intervals. Biodistribution experiments carried out in mice showed maximum uptake of 6.12 ± 1.22%ID/g at 45 min postinjection. For [188Re]-CDTMP, total skeletal uptake was 8.12 ± 1.11%ID/g observed at 1 h postinjection from biodistribution data. High renal uptake confirms renal route of excretion. A good hydroxyapatite binding too was seen for both the complexes. No evidence of destruction or adverse functioning of vital organs was observed for the 188Re complex. Conclusion [68Ga]-CDTMP complex can be used as a promising PET bone imaging agent and [188Re]-CDTMP as a surrogate moiety for therapeutic application. Owing to the short half-life of 68Ga (68 min), cyclotron-independent radiopharmacy, fast clearance, and rapid renal excretion as evidenced in preclinical animal models. Very low myelotoxicity and highly selective bone uptake prove the potential of [188Re]-CDTMP for therapeutic application.
Collapse
Affiliation(s)
- Ambika P Jaswal
- Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Delhi, India
| | - Virendra K Meena
- Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Delhi, India
| | - Surbhi Prakash
- Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Delhi, India
| | - Ankita Pandey
- Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Delhi, India
| | | | - Anil K Mishra
- Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Delhi, India
| | - Puja P Hazari
- Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Delhi, India
| |
Collapse
|
24
|
Liu J, Zeng Y, Shi S, Xu L, Zhang H, Pathak JL, Pan Y. Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone. Int J Nanomedicine 2017; 12:3561-3575. [PMID: 28507436 PMCID: PMC5428813 DOI: 10.2147/ijn.s133787] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Treatment of cancer metastasized to bone is still a challenge due to hydrophobicity, instability, and lack of target specificity of anticancer drugs. Poly (ethylene glycol)-poly (ε-caprolactone) polymer (PEG-PCL) is an effective, biodegradable, and biocompatible hydrophobic drug carrier, but lacks bone specificity. Polyaspartic acid with eight peptide sequences, that is, (Asp)8, has a strong affinity to bone surface. The aim of this study was to synthesize (Asp)8-PEG-PCL nanoparticles as a bone-specific carrier of hydrophobic drugs to treat cancer metastasized to bone. 1H nuclear magnetic resonance, Fourier transform infrared spectroscopy, and transmission electron microscopy data showed that (Asp)8-PEG-PCL nanoparticles (size 100 nm) were synthesized successfully. (Asp)8-PEG-PCL nanoparticles did not promote erythrocyte aggregation. Fluorescence microscopy showed clear uptake of Nile red-loaded (Asp)8-PEG-PCL nanoparticles by cancer cells. (Asp)8-PEG-PCL nanoparticles did not show cytotoxic effect on MG63 and human umbilical vein endothelial cells at the concentration of 10-800 μg/mL. (Asp)8-PEG-PCL nanoparticles bound with hydroxyapatite 2-fold more than PEG-PCL. Intravenously injected (Asp)8-PEG-PCL nanoparticles accumulated 2.7-fold more on mice tibial bone, in comparison to PEG-PCL. Curcumin is a hydrophobic anticancer drug with bone anabolic properties. Curcumin was loaded in the (Asp)8-PEG-PCL. (Asp)8-PEG-PCL showed 11.07% loading capacity and 95.91% encapsulation efficiency of curcumin. The curcumin-loaded (Asp)8-PEG-PCL nanoparticles gave sustained release of curcumin in high dose for >8 days. The curcumin-loaded (Asp)8-PEG-PCL nanoparticles showed strong antitumorigenic effect on MG63, MCF7, and HeLa cancer cells. In conclusion, (Asp)8-PEG-PCL nanoparticles were biocompatible, permeable in cells, a potent carrier, and an efficient releaser of hydrophobic anticancer drug and were bone specific. The curcumin-loaded (Asp)8-PEG-PCL nanoparticles showed strong antitumorigenic ability in vitro. Therefore, (Asp)8-PEG-PCL nanoparticles could be a potent carrier of hydrophobic anticancer drugs to treat the cancer metastasized to bone.
Collapse
Affiliation(s)
| | | | - Shuai Shi
- Institute of Biomedical Engineering, School of Ophthalmology & Optometry and Eye Hospital, Wenzhou Medical University
| | - Lihua Xu
- The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
| | - Hualin Zhang
- College of Stomatology, Ningxia Medical University, Yinchuan
| | - Janak L Pathak
- School of Pharmaceutical Science and Technology, Health Sciences Platform, Tianjin University, Tianjin, People's Republic of China
| | | |
Collapse
|
25
|
Bidentate iminodiacetate modified dendrimer for bone imaging. Bioorg Med Chem Lett 2017; 27:1252-1255. [PMID: 28153357 DOI: 10.1016/j.bmcl.2017.01.059] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2016] [Revised: 01/13/2017] [Accepted: 01/16/2017] [Indexed: 11/24/2022]
Abstract
A new dendrimer probe was designed for bone imaging. Bidentate iminodiacetate groups were introduced to the probe to obtain strong bind to bones. The assembled dendrimeric probe, with four iminodiacetate moieties and a fluorescent tag, displayed good selectivity to hydroxyapatite, calcium oxalate and calcium phosphate salts. In mice, the probe offered vivid skeletal details after intravenous delivery.
Collapse
|
26
|
Carbone EJ, Rajpura K, Allen BN, Cheng E, Ulery BD, Lo KWH. Osteotropic nanoscale drug delivery systems based on small molecule bone-targeting moieties. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2016; 13:37-47. [PMID: 27562211 DOI: 10.1016/j.nano.2016.08.015] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/11/2015] [Revised: 08/02/2016] [Accepted: 08/05/2016] [Indexed: 12/22/2022]
Abstract
Bone-targeted drug delivery is an active research area because successful clinical applications of this technology can significantly advance the treatment of bone injuries and disorders. Molecules with bone-targeting potential have been actively investigated as promising moieties in targeted drug delivery systems. In general, bone-targeting molecules are characterized by their high affinity for bone and their predisposition to persist in bone tissue for prolonged periods, while maintaining low systemic concentrations. Proteins, such as monoclonal antibodies, have shown promise as bone-targeting molecules; however, they suffer from several limitations including large molecular size, high production cost, and undesirable immune responses. A viable alternative associated with significantly less side effects is the use of small molecule-based targeting moieties. This review provides a summary of recent findings regarding small molecule compounds with bone-targeting capacity, as well as nanoscale targeted drug delivery approaches employing these molecules.
Collapse
Affiliation(s)
- Erica J Carbone
- Institute for Regenerative Engineering, University of Connecticut Health Center, School of Medicine, Farmington, CT, USA; The Raymond and Beverly Sackler Center for Biomedical, Biological, Physical and Engineering Sciences, University of Connecticut Health Center, School of Medicine, Farmington, CT, USA; Division of Endocrinology, Department of Medicine, University of Connecticut Health Center, School of Medicine, Farmington, CT, USA; UConn Stem Cell Institute, University of Connecticut Health Center, Farmington, CT, USA
| | - Komal Rajpura
- Institute for Regenerative Engineering, University of Connecticut Health Center, School of Medicine, Farmington, CT, USA; The Raymond and Beverly Sackler Center for Biomedical, Biological, Physical and Engineering Sciences, University of Connecticut Health Center, School of Medicine, Farmington, CT, USA; Connecticut Institute for Clinical and Translational Science, University of Connecticut Health Center, Farmington, CT, USA
| | - Brittany N Allen
- Department of Bioengineering, University of Missouri, Columbia, MO, USA
| | - Emily Cheng
- Department of Chemical Engineering, University of Missouri, Columbia, MO, USA
| | - Bret D Ulery
- Department of Chemical Engineering, University of Missouri, Columbia, MO, USA
| | - Kevin W-H Lo
- Institute for Regenerative Engineering, University of Connecticut Health Center, School of Medicine, Farmington, CT, USA; The Raymond and Beverly Sackler Center for Biomedical, Biological, Physical and Engineering Sciences, University of Connecticut Health Center, School of Medicine, Farmington, CT, USA; Division of Endocrinology, Department of Medicine, University of Connecticut Health Center, School of Medicine, Farmington, CT, USA; UConn Stem Cell Institute, University of Connecticut Health Center, Farmington, CT, USA; Department of Biomedical Engineering, University of Connecticut, School of Engineering, Storrs, CT, USA; Connecticut Institute for Clinical and Translational Science, University of Connecticut Health Center, Farmington, CT, USA.
| |
Collapse
|
27
|
Zhang L, Cao H, Zhang J, Yang C, Hu T, Li H, Yang W, He G, Song X, Tong A, Guo G, Li R, Jiang Y, Liu J, Cai L, Zheng Y. Comparative study of (Asp)7-CHOL-modified liposome prepared using pre-insertion and post-insertion methods for bone targeting in vivo. J Drug Target 2016; 25:149-155. [PMID: 27416786 DOI: 10.1080/1061186x.2016.1212201] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Specific delivery of drugs to bone tissue is very challenging due to the architecture and structure of bone tissue. A seven-repeat sequence of aspartate, a representative bone-targeting oligopeptide, is preferentially used for targeted therapy for bone diseases. In this study, Asp7-cholesterol((Asp)7-CHOL) was synthesized and (Asp)7-CHOL-modified liposome loaded with doxorubicin (DOX) was successfully prepared using both pre-insertion (pre-L) and post-insertion (post-L) methods. The formulation was optimized according to particle size, zeta potential and the drug-loading efficiency of the liposome. In addition, the bone affinity of the (Asp)7-CHOL-modified liposome was evaluated using a hydroxyapatite (HA) absorption method. The results suggested that (Asp)7-CHOL-modified liposome show excellent HA absorption; pre-L showed slightly higher HA binding than post-L. However, post-L had a higher DOX entrapment efficiency than pre-L. In vivo imaging further demonstrated that pre-L showed a higher bone-targeting efficiency than post-L, which was consistent with in vitro results. In all, (Asp)7-CHOL-modified liposome showed excellent bone-targeting activity, suggesting their potential for use as a drug delivery system for bone disease-targeted therapies.
Collapse
Affiliation(s)
- Lijing Zhang
- a State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy , West China Hospital, Sichuan University , Chengdu , PR China
| | - Hua Cao
- a State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy , West China Hospital, Sichuan University , Chengdu , PR China
| | - Jiaxin Zhang
- a State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy , West China Hospital, Sichuan University , Chengdu , PR China
| | - Chengli Yang
- a State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy , West China Hospital, Sichuan University , Chengdu , PR China
| | - Tingting Hu
- a State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy , West China Hospital, Sichuan University , Chengdu , PR China
| | - Huili Li
- a State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy , West China Hospital, Sichuan University , Chengdu , PR China
| | - Wu Yang
- a State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy , West China Hospital, Sichuan University , Chengdu , PR China
| | - Gu He
- a State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy , West China Hospital, Sichuan University , Chengdu , PR China
| | - Xiangrong Song
- a State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy , West China Hospital, Sichuan University , Chengdu , PR China
| | - Aiping Tong
- a State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy , West China Hospital, Sichuan University , Chengdu , PR China
| | - Gang Guo
- a State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy , West China Hospital, Sichuan University , Chengdu , PR China
| | - Rui Li
- a State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy , West China Hospital, Sichuan University , Chengdu , PR China
| | - Yu Jiang
- a State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy , West China Hospital, Sichuan University , Chengdu , PR China.,b Department of Pharmacy , Hospital of the University of Electronic Science and Technology of China and Sichuan Provincial People's Hospital , Chengdu , PR China
| | - Jiyan Liu
- a State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy , West China Hospital, Sichuan University , Chengdu , PR China.,b Department of Pharmacy , Hospital of the University of Electronic Science and Technology of China and Sichuan Provincial People's Hospital , Chengdu , PR China
| | - Lulu Cai
- a State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy , West China Hospital, Sichuan University , Chengdu , PR China.,b Department of Pharmacy , Hospital of the University of Electronic Science and Technology of China and Sichuan Provincial People's Hospital , Chengdu , PR China
| | - Yu Zheng
- a State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy , West China Hospital, Sichuan University , Chengdu , PR China
| |
Collapse
|
28
|
Ogawa K. Biocomplexes in radiochemistry. PHYSICAL SCIENCES REVIEWS 2016. [DOI: 10.1515/psr-2016-0005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
29
|
Ogawa K, Yu J, Ishizaki A, Yokokawa M, Kitamura M, Kitamura Y, Shiba K, Odani A. Radiogallium Complex-Conjugated Bifunctional Peptides for Detecting Primary Cancer and Bone Metastases Simultaneously. Bioconjug Chem 2015; 26:1561-70. [PMID: 26087328 DOI: 10.1021/acs.bioconjchem.5b00186] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
(68)Ga (T(1/2) = 68 min, a generator-produced nuclide) is an interesting radionuclide for clinical positron emission tomography (PET). Recently, it was reported that radiogallium-labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated (Asp)n peptide [Ga-DOTA-(Asp)n] has great potential for bone metastases imaging. In the current study, a compound containing an aspartic acid peptide linker (D11) as a carrier to bone metastases, an RGD peptide [c(RGDfK) peptide] as a carrier to the primary cancer, and Ga-DOTA as a stable radiometal complex for imaging in one molecule, Ga-DOTA-D11-c(RGDfK), was designed, prepared, and evaluated to detect both the primary cancer and bone metastases simultaneously using (67)Ga, which is easy to handle. After DOTA-D11-c(RGDfK) was synthesized using Fmoc-based solid-phase methodology, (67)Ga-DOTA-D11-c(RGDfK) was prepared by complexing DOTA-D11-c(RGDfK) with (67)Ga. Hydroxyapatite binding assays, integrin binding assays, biodistribution experiments, and single photon emission tomography (SPECT) imaging using tumor-bearing mice were performed using (67)Ga-DOTA-D11-c(RGDfK). (67)Ga-DOTA-D11-c(RGDfK) was prepared with a radiochemical purity of >97%. In vitro, (67)Ga-DOTA-D11-c(RGDfK) had a high affinity for hydroxyapatite and αvβ3 integrin. In vivo, (67)Ga-DOTA-D11-c(RGDfK) exhibited high uptake in bone and tumor. The accumulation of (67)Ga-DOTA-D11-c(RGDfK) in tumor decreased when it was co-injected with c(RGDfK) peptide. (68)Ga-DOTA-D11-c(RGDfK) has great potential as a PET tracer for the diagnosis of both the primary cancer and bone metastases simultaneously.
Collapse
Affiliation(s)
- Kazuma Ogawa
- †Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-1192, Japan.,‡Institute for Frontier Science Initiative, Kanazawa University, Kanazawa 920-1192, Japan
| | - Jing Yu
- †Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-1192, Japan
| | - Atsushi Ishizaki
- †Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-1192, Japan
| | - Masaru Yokokawa
- †Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-1192, Japan
| | - Masanori Kitamura
- †Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-1192, Japan
| | - Yoji Kitamura
- §Advanced Science Research Center, Kanazawa University, Kanazawa 920-8640, Japan
| | - Kazuhiro Shiba
- §Advanced Science Research Center, Kanazawa University, Kanazawa 920-8640, Japan
| | - Akira Odani
- †Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-1192, Japan
| |
Collapse
|
30
|
Well-designed bone-seeking radiolabeled compounds for diagnosis and therapy of bone metastases. BIOMED RESEARCH INTERNATIONAL 2015; 2015:676053. [PMID: 26075256 PMCID: PMC4446473 DOI: 10.1155/2015/676053] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/24/2014] [Revised: 10/04/2014] [Accepted: 10/08/2014] [Indexed: 11/18/2022]
Abstract
Bone-seeking radiopharmaceuticals are frequently used as diagnostic agents in nuclear medicine, because they can detect bone disorders before anatomical changes occur. Furthermore, their effectiveness in the palliation of metastatic bone cancer pain has been demonstrated in the clinical setting. With the aim of developing superior bone-seeking radiopharmaceuticals, many compounds have been designed, prepared, and evaluated. Here, several well-designed bone-seeking compounds used for diagnostic and therapeutic use, having the concept of radiometal complexes conjugated to carrier molecules to bone, are reviewed.
Collapse
|
31
|
Mirzaei A, Jalilian AR, Badbarin A, Mazidi M, Mirshojaei F, Geramifar P, Beiki D. Optimized production and quality control of 68Ga-EDTMP for small clinical trials. Ann Nucl Med 2015; 29:506-11. [DOI: 10.1007/s12149-015-0971-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2015] [Accepted: 04/06/2015] [Indexed: 01/26/2023]
|
32
|
Ossipov DA. Bisphosphonate-modified biomaterials for drug delivery and bone tissue engineering. Expert Opin Drug Deliv 2015; 12:1443-58. [PMID: 25739860 DOI: 10.1517/17425247.2015.1021679] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Bisphosphonates (BPs) were introduced 45 years ago as anti-osteoporotic drugs and during the last decade have been utilized as bone-targeting groups in systemic treatment of bone diseases. Very recently, strategies of chemical immobilization of BPs in hydrogels and nanocomposites for bone tissue engineering emerged. These strategies opened new applications of BPs in bone tissue engineering. AREAS COVERED Conjugates of BPs to different drug molecules, imaging agents, proteins and polymers are discussed in terms of specific targeting to bone and therapeutic affect induced by the resulting prodrugs in comparison with the parent drugs. Conversion of these conjugates into hydrogel scaffolds is also presented along with the application of the resulting materials for bone tissue engineering. EXPERT OPINION Calcium-binding properties of BPs can be successfully extended via different conjugation strategies not only for purposes of bone targeting, but also in supramolecular assembly affording either new nanocarriers or bulk nanocomposite scaffolds. Interaction between carrier-linked BPs and drug molecules should also be considered for the control of release of these molecules and their optimized delivery. Bone-targeting properties of BP-functionalized nanomaterials should correspond to bone adhesive properties of their bulk analogs.
Collapse
Affiliation(s)
- Dmitri A Ossipov
- Uppsala University, Division of Polymer Chemistry, Department of Chemistry-Ångström, Science for Life Laboratory , Uppsala, SE 751 21 , Sweden +46 18 417 7335 ;
| |
Collapse
|
33
|
Velikyan I. Continued rapid growth in68Ga applications: update 2013 to June 2014. J Labelled Comp Radiopharm 2015; 58:99-121. [DOI: 10.1002/jlcr.3250] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2014] [Revised: 11/13/2014] [Accepted: 11/21/2014] [Indexed: 12/21/2022]
Affiliation(s)
- Irina Velikyan
- Preclinical PET Platform, Department of Medicinal Chemistry; Uppsala University; SE-75183 Uppsala Sweden
- Department of Radiology, Oncology and Radiation Science; Uppsala University; SE-75285 Uppsala Sweden
- PET-Centre, Centre for Medical Imaging; Uppsala University Hospital; SE-75185 Uppsala Sweden
| |
Collapse
|
34
|
Jiang T, Yu X, Carbone EJ, Nelson C, Kan HM, Lo KWH. Poly aspartic acid peptide-linked PLGA based nanoscale particles: Potential for bone-targeting drug delivery applications. Int J Pharm 2014; 475:547-57. [DOI: 10.1016/j.ijpharm.2014.08.067] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2014] [Revised: 08/24/2014] [Accepted: 08/27/2014] [Indexed: 12/25/2022]
|
35
|
A (68)Ga complex based on benzofuran scaffold for the detection of β-amyloid plaques. Bioorg Med Chem Lett 2014; 24:4834-7. [PMID: 25227717 DOI: 10.1016/j.bmcl.2014.08.058] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2014] [Revised: 08/21/2014] [Accepted: 08/26/2014] [Indexed: 02/02/2023]
Abstract
Since the imaging of β-amyloid (Aβ) plaques in the brain is believed to be a useful tool for the early diagnosis of Alzheimer's disease (AD), a number of imaging probes to detect Aβ plaques have been developed. Because the radionuclide (68)Ga (t1/2=68 min) for PET imaging could become an attractive alternative to (11)C and (18)F, we designed and synthesized a benzofuran derivative conjugated with a (68)Ga complex ((68)Ga-DOTA-C3-BF) as a novel Aβ imaging probe. In an in vitro binding assay, Ga-DOTA-C3-BF showed high affinity for Aβ(1-42) aggregates (Ki=10.8 nM). The Ga-DOTA-C3-BF clearly stained Aβ plaques in a section of Tg2576 mouse, reflecting the affinity for Aβ(1-42) aggregates in vitro. In a biodistribution study in normal mice, (68)Ga-DOTA-C3-BF displayed low initial uptake (0.45% ID/g) in the brain at 2 min post-injection. While improvement of the brain uptake of (68)Ga complexes appears to be essential, these results suggest that novel PET imaging probes that include (68)Ga as the radionuclide for PET may be feasible.
Collapse
|